Amedeo Smart

Free Medical Literature Service

 

Amedeo

Gynecology
  Free Subscription

Articles published in
Br J Cancer
    January 2026
  1. WANG M, Fan J, Mu B, Zeng Y, et al
    HDAC5 stabilization by tubeimoside I suppresses cervical cancer metastasis via inhibiting H3K27ac/KPNA2 axis.
    Br J Cancer. 2026 Jan 8. doi: 10.1038/s41416-025-03328.
    >> Share

  2. BOWDEN SJ, Ellis LB, Cuming T, Brogden D, et al
    Multizonal intraepithelial neoplasia of the lower genital tract and anus in women: terminology for defining the disease, an introduction by the British Society for Colposcopy and Cervical Pathology (BSCCP), International Anal Neoplasia Society (IANS),
    Br J Cancer. 2026;134:177-184.
    >> Share

  3. PEI J, Fan J, Liao Y, Li M, et al
    Prognostic value of MYBL2 and its potential implications for immunotherapy: a study of bioinformatics and experimental validation.
    Br J Cancer. 2026;134:317-330.
    >> Share

    December 2025
  4. DE SOUZA WAGNER PH, Matheus GTFU, Monteiro Ribeiro D, Figueroa Magalhaes MC, et al
    Breast cancer incidence and subtype patterns among BRCA-mutated ovarian cancer patients: a systematic review and meta-analysis.
    Br J Cancer. 2025 Dec 23. doi: 10.1038/s41416-025-03320.
    >> Share

    November 2025
  5. GORI S, Venturelli F, Carozzi F, Giorgi Rossi P, et al
    Correction: Italian guidelines for cervical cancer screening. Multisocietal recommendations on the use of biomarkers in HPV screening with risk-based approach and GRADE methodology.
    Br J Cancer. 2025 Nov 11. doi: 10.1038/s41416-025-03250.
    >> Share

  6. LOKMAN NA, Macpherson AM, Thompson AR, Price ZK, et al
    Proteomics analysis of serum extracellular vesicle identifies UCHL1 as a potential therapeutic target for high grade serous ovarian cancer.
    Br J Cancer. 2025 Nov 5. doi: 10.1038/s41416-025-03244.
    >> Share

  7. COLIN-LEITZINGER C, Aranzabal O, Johnson CE, Alberg AJ, et al
    Use of non-prescription analgesic medications and survival among Black women with ovarian cancer.
    Br J Cancer. 2025 Nov 5. doi: 10.1038/s41416-025-03254.
    >> Share

    October 2025
  8. WANG W, Gao M, Gao Y, Zheng H, et al
    Integrating homologous recombination deficiency subtyping with TCGA molecular classification for enhanced prognostic stratification and personalised therapy in endometrial cancer.
    Br J Cancer. 2025 Oct 14. doi: 10.1038/s41416-025-03179.
    >> Share

  9. WARD MP, Lewis F, O'Gorman C, Norris LA, et al
    Circulating tumour cells are a prognostic indicator in advanced high-grade serous ovarian cancer and are associated with platelets and immune cells following dissemination.
    Br J Cancer. 2025 Oct 10. doi: 10.1038/s41416-025-03227.
    >> Share

  10. DURAN GE, Wang YC, Moisan F, Francisco EB, et al
    Editorial Expression of Concern: Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transition.
    Br J Cancer. 2025 Oct 6. doi: 10.1038/s41416-025-03231.
    >> Share

  11. BAENA A, Picconi MA, Mendoza L, Ferrera A, et al
    Short-term repeat HPV testing for triaging HPV-positive women in cervical cancer screening.
    Br J Cancer. 2025 Oct 3. doi: 10.1038/s41416-025-03193.
    >> Share

  12. CHANG YH, Bresnahan ST, Taylor Head S, Harrison TA, et al
    Isoform-level analyses of 6 cancers uncover extensive genetic risk mechanisms undetected at the gene-level.
    Br J Cancer. 2025;133:874-885.
    >> Share

    September 2025
  13. FAURE-CONTER C, Lopes LF, Gao Y, Calaminus G, et al
    Vaginal germ cell tumors: results from the international retrospective VAGIPED study.
    Br J Cancer. 2025 Sep 24. doi: 10.1038/s41416-025-03201.
    >> Share

  14. WU R, Arendse KD, Hamdani T, Walter FM, et al
    Cost-effectiveness of CA125- and age-informed risk-based triage for ovarian cancer detection in primary care.
    Br J Cancer. 2025 Sep 17. doi: 10.1038/s41416-025-03166.
    >> Share

  15. ARENDSE KD, Walter FM, Abel G, Rous B, et al
    CA125 and age-based models for ovarian cancer detection in primary care: a population-based external validation study.
    Br J Cancer. 2025 Sep 17. doi: 10.1038/s41416-025-03165.
    >> Share

  16. GORI S, Venturelli F, Carozzi F, Giorgi Rossi P, et al
    Italian guidelines for cervical cancer screening. Multisocietal recommendations on the use of biomarkers in HPV screening with risk-based approach and GRADE methodology.
    Br J Cancer. 2025 Sep 11. doi: 10.1038/s41416-025-03161.
    >> Share

  17. MATHEWS CS, Sargent A, Cuschieri K, Rebolj M, et al
    HPValidate-human papillomavirus testing with DNA and mRNA assays on self-collected samples in cervical screening: comparison of test characteristics on three self-sampling devices.
    Br J Cancer. 2025;133:665-673.
    >> Share

    August 2025
  18. MULUGETA A, Stacey D, Lumsden AL, Madakkatel I, et al
    Protein markers of ovarian cancer and its subtypes: insights from proteome-wide Mendelian randomisation analysis.
    Br J Cancer. 2025 Aug 28. doi: 10.1038/s41416-025-03143.
    >> Share

  19. STOER NC, Vangen S, Singh D, Fortner RT, et al
    Correction: Menopausal hormone therapy and breast cancer risk: a population-based cohort study of 1.3 million women in Norway.
    Br J Cancer. 2025 Aug 20. doi: 10.1038/s41416-025-03038.
    >> Share

    July 2025
  20. SOOI K, Tan TZ, Kim JW, Lee JY, et al
    A phase 1b, multicentre, dose escalation, safety and pharmacokinetics study of tilvestamab (BGB149) in relapsed, platinum-resistant, high-grade serous ovarian cancer (PROC) patients.
    Br J Cancer. 2025 Jul 22. doi: 10.1038/s41416-025-03090.
    >> Share

  21. YIN C, Adenekan TA, Deng C, Hansen J, et al
    Application of an obstetric comorbidity index to predict childhood cancer risk: a population based case-control study in Denmark.
    Br J Cancer. 2025 Jul 21. doi: 10.1038/s41416-025-03120.
    >> Share

  22. FICORELLA L, Yang X, Mavaddat N, Carver T, et al
    Adapting the BOADICEA breast and ovarian cancer risk models for the ethnically diverse UK population.
    Br J Cancer. 2025 Jul 17. doi: 10.1038/s41416-025-03117.
    >> Share

    June 2025
  23. STANGE C, Dreyer TF, Riedel M, Elsen F, et al
    PARP inhibitor-induced anti-tumour chemokine response is suppressed by dipeptidyl peptidase 4 (DPP4) in ovarian cancer.
    Br J Cancer. 2025 Jun 27. doi: 10.1038/s41416-025-03076.
    >> Share

  24. LIU Y, Chen Z, Duan Y, Shao Z, et al
    Spliceosomal GTPase EFTUD2 mediates DDX41 intron retention to promote the malignant progression of ovarian cancer.
    Br J Cancer. 2025 Jun 24. doi: 10.1038/s41416-025-03079.
    >> Share

  25. NARAYANAN B, Buddenkotte T, Smith H, Shah M, et al
    Growth kinetics of high-grade serous ovarian cancer: implications for early detection.
    Br J Cancer. 2025 Jun 12. doi: 10.1038/s41416-025-03082.
    >> Share

    May 2025
  26. SCHIEMER R, Grant J, Shafiee MN, Phang S, et al
    Infrared and Raman spectroscopy of blood plasma for rapid endometrial cancer detection.
    Br J Cancer. 2025 May 18. doi: 10.1038/s41416-025-03050.
    >> Share

  27. TYRAKIS PA, Kampjut D, Steele GF, Lindstrom HJG, et al
    Multi-node inhibition targeting mTORC1, mTORC2 and PI3Kalpha potently inhibits the PI3K/AKT/mTOR pathway in endometrial and breast cancer models.
    Br J Cancer. 2025 May 13. doi: 10.1038/s41416-025-03035.
    >> Share

    April 2025
  28. TREWIN-NYBRATEN CB, Leithe S, Paulsen T, Langseth H, et al
    Ovarian cancer survival by residual disease following cytoreductive surgery: a nationwide study in Norway.
    Br J Cancer. 2025 Apr 26. doi: 10.1038/s41416-025-03018.
    >> Share

  29. LAGA T, Van Rompuy AS, Busschaert P, Marquina G, et al
    Single-cell profiling in ovarian germ cell and sex cord-stromal tumours.
    Br J Cancer. 2025 Apr 23. doi: 10.1038/s41416-025-03012.
    >> Share

  30. SU H, Jin X, Kong L, You Y, et al
    The triage role of cytological DNA methylation in women with non-16/18, specifically genotyping high-risk HPV infection.
    Br J Cancer. 2025 Apr 10. doi: 10.1038/s41416-025-03005.
    >> Share

    March 2025
  31. PIGNATA S, Oza A, Hall G, Pardo B, et al
    Overall survival with maintenance olaparib in platinum-sensitive relapsed ovarian cancer by somatic or germline BRCA and homologous recombination repair mutation status.
    Br J Cancer. 2025 Mar 17. doi: 10.1038/s41416-025-02966.
    >> Share

  32. YE X, Zheng J, Hu D, Liu L, et al
    Identification of increased dedifferentiation along the Prom1+ cancer cells in Mullerian adenosarcoma with sarcomatous overgrowth.
    Br J Cancer. 2025;132:438-449.
    >> Share

    December 2024
  33. MERRITT MA, Abe SK, Islam MR, Rahman MS, et al
    Reproductive factors and risk of epithelial ovarian cancer: results from the Asia Cohort Consortium.
    Br J Cancer. 2024 Dec 20. doi: 10.1038/s41416-024-02924.
    >> Share

  34. LIU C, Reger M, Fan H, Wang J, et al
    Dietary intake of isoflavones and coumestrol and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.
    Br J Cancer. 2024 Dec 16. doi: 10.1038/s41416-024-02929.
    >> Share

  35. XU Q, Kowalski J
    Non-B DNA-informed mutation burden as a marker of treatment response and outcome in cancer.
    Br J Cancer. 2024;131:1825-1832.
    >> Share

    November 2024
  36. MORGAN RD, Wang X, Barnes BM, Spurgeon L, et al
    Germline BRCA1/2 status and chemotherapy response score in high-grade serous ovarian cancer.
    Br J Cancer. 2024 Nov 16. doi: 10.1038/s41416-024-02874.
    >> Share

  37. TAN R, Wen M, Yang W, Zhan D, et al
    Integrated proteomics and scRNA-seq analyses of ovarian cancer reveal molecular subtype-associated cell landscapes and immunotherapy targets.
    Br J Cancer. 2024 Nov 15. doi: 10.1038/s41416-024-02894.
    >> Share

  38. ZAHID MU, Waguespack M, Harman RC, Kercher EM, et al
    Fractionated photoimmunotherapy stimulates an anti-tumour immune response: an integrated mathematical and in vitro study.
    Br J Cancer. 2024;131:1378-1386.
    >> Share

    October 2024
  39. HIRAHARA Y, Shimizu K, Yamasaki S, Iyoda T, et al
    Crucial immunological roles of the invasion front in innate and adaptive immunity in cervical cancer.
    Br J Cancer. 2024 Oct 29. doi: 10.1038/s41416-024-02877.
    >> Share

  40. SUN Y, Yin Z, Li S, Wu L, et al
    Losartan rewires the tumor-immune microenvironment and suppresses IGF-1 to overcome resistance to chemo-immunotherapy in ovarian cancer.
    Br J Cancer. 2024 Oct 5. doi: 10.1038/s41416-024-02863.
    >> Share

    September 2024
  41. YANG X, Wu Y, Ficorella L, Wilcox N, et al
    Validation of the BOADICEA model for epithelial tubo-ovarian cancer risk prediction in UK Biobank.
    Br J Cancer. 2024 Sep 18. doi: 10.1038/s41416-024-02851.
    >> Share

  42. KRISTELEIT R, Leary A, Oaknin A, Redondo A, et al
    PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers.
    Br J Cancer. 2024;131:820-831.
    >> Share

  43. SMITH HL, Willmore E, Prendergast L, Curtin NJ, et al
    ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors.
    Br J Cancer. 2024;131:905-917.
    >> Share

  44. SUVAAL I, Hummel SB, Mens JM, Tuijnman-Raasveld CC, et al
    Efficacy of a nurse-led sexual rehabilitation intervention for women with gynaecological cancers receiving radiotherapy: results of a randomised trial.
    Br J Cancer. 2024;131:808-819.
    >> Share

    August 2024
  45. TAKAMATSU S, Hillman RT, Yoshihara K, Baba T, et al
    Molecular classification of ovarian high-grade serous/endometrioid carcinomas through multi-omics analysis: JGOG3025-TR2 study.
    Br J Cancer. 2024 Aug 30. doi: 10.1038/s41416-024-02837.
    >> Share

  46. ZHUO L, Meng F, Sun K, Zhou M, et al
    Integrated immuno-transcriptomic analysis of ovarian cancer identifies a four-chemokine-dominated subtype with antitumor immune-active phenotype and favorable prognosis.
    Br J Cancer. 2024 Aug 2. doi: 10.1038/s41416-024-02803.
    >> Share

    July 2024
  47. NAGLE CM, Ibiebele TI, Bandera EV, Cramer D, et al
    Pre-diagnosis tea and coffee consumption and survival after a diagnosis of ovarian cancer: results from the Ovarian Cancer Association Consortium.
    Br J Cancer. 2024 Jul 18. doi: 10.1038/s41416-024-02792.
    >> Share

    June 2024
  48. ARONSON SL, Walker C, Thijssen B, van de Vijver KK, et al
    Tumour microenvironment characterisation to stratify patients for hyperthermic intraperitoneal chemotherapy in high-grade serous ovarian cancer (OVHIPEC-1).
    Br J Cancer. 2024 Jun 12. doi: 10.1038/s41416-024-02731.
    >> Share

  49. QIU L, Li R, Wang Y, Lu Z, et al
    PTEN inhibition enhances sensitivity of ovarian cancer cells to the poly (ADP-ribose) polymerase inhibitor by suppressing the MRE11-RAD50-NBN complex.
    Br J Cancer. 2024 Jun 12. doi: 10.1038/s41416-024-02749.
    >> Share

    May 2024
  50. STOER NC, Vangen S, Singh D, Fortner RT, et al
    Menopausal hormone therapy and breast cancer risk: a population-based cohort study of 1.3 million women in Norway.
    Br J Cancer. 2024 May 13. doi: 10.1038/s41416-024-02590.
    >> Share

  51. KENKHUIS MF, Stelten S, Hartman YA, Brouwer CG, et al
    Effects of a combined exercise and dietary intervention on body composition, physical functioning and fatigue in patients with ovarian cancer: results of the PADOVA trial.
    Br J Cancer. 2024 May 8. doi: 10.1038/s41416-024-02694.
    >> Share

  52. HERMAN L, Amo A, Legois B, Di Carlo C, et al
    A cellular model provides insights into the pathogenicity of the oncogenic FOXL2 somatic variant p.Cys134Trp.
    Br J Cancer. 2024;130:1453-1462.
    >> Share

  53. REBOLJ M, Brentnall AR, Cuschieri K
    Predictable changes in the accuracy of human papillomavirus tests after vaccination: review with implications for performance monitoring in cervical screening.
    Br J Cancer. 2024;130:1733-1743.
    >> Share

  54. NG CW, Tsang YTM, Gershenson DM, Wong KK, et al
    The prognostic value of MEK pathway-associated estrogen receptor signaling activity for female cancers.
    Br J Cancer. 2024;130:1875-1884.
    >> Share

    April 2024
  55. DHAR C, Ramachandran P, Xu G, Pickering C, et al
    Diagnosing and staging epithelial ovarian cancer by serum glycoproteomic profiling.
    Br J Cancer. 2024 Apr 24. doi: 10.1038/s41416-024-02644.
    >> Share

  56. PORTNOY A, Pedersen K, Kim JJ, Burger EA, et al
    Vaccination and screening strategies to accelerate cervical cancer elimination in Norway: a model-based analysis.
    Br J Cancer. 2024 Apr 20. doi: 10.1038/s41416-024-02682.
    >> Share

  57. KMENT J, Newsted D, Young S, Vermeulen MC, et al
    Blockade of TGF-beta and PD-L1 by bintrafusp alfa promotes survival in preclinical ovarian cancer models by promoting T effector and NK cell responses.
    Br J Cancer. 2024 Apr 15. doi: 10.1038/s41416-024-02677.
    >> Share

  58. TIAN Y, Lin Y, Qu C, Arndt V, et al
    Genetic risk impacts the association of menopausal hormone therapy with colorectal cancer risk.
    Br J Cancer. 2024 Apr 1. doi: 10.1038/s41416-024-02638.
    >> Share

    March 2024
  59. ROQUE DM, Siegel ER, Buza N, Bellone S, et al
    Correction: Randomised phase II trial of weekly ixabepilone +/- biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.
    Br J Cancer. 2024 Mar 4. doi: 10.1038/s41416-024-02628.
    >> Share

  60. MATOBA Y, Zarrella DT, Pooladanda V, Azimi Mohammadabadi M, et al
    Targeting Galectin 3 illuminates its contributions to the pathology of uterine serous carcinoma.
    Br J Cancer. 2024 Mar 4. doi: 10.1038/s41416-024-02621.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016